keyword
MENU ▼
Read by QxMD icon Read
search

abatacept rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/28199343/long-term-treatment-with-abatacept-or-tocilizumab-does-not-increase-epstein-barr-virus-load-in-patients-with-rheumatoid-arthritis-a-three-years-retrospective-study
#1
Nathalie Balandraud, Gaetan Texier, Emmanuel Massy, Olivier Muis-Pistor, Marielle Martin, Isabelle Auger, Marie-Caroline Guzian, Sandrine Guis, Thao Pham, Jean Roudier
BACKGROUND: Epstein-Barr Virus (EBV) is a widely disseminated lymphotropic herpes virus implicated in benign and malignant disorders. In transplant patients, immunosuppressive drugs (cyclosporine) diminish control of EBV replication, potentially leading to lymphoproliferative disorders (LPD). Rheumatoid arthritis (RA) patients have impaired control of EBV infection and have EBV load ten times higher than controls. As post transplant patients, patients with RA have increased risk of developing lymphomas...
2017: PloS One
https://www.readbyqxmd.com/read/28183330/th17-and-cd24-hi-cd27-regulatory-b-lymphocytes-are-biomarkers-of-response-to-biologics-in-rheumatoid-arthritis
#2
Sarah Salomon, Caroline Guignant, Pierre Morel, Gauthier Flahaut, Clément Brault, Clément Gourguechon, Patrice Fardellone, Jean-Pierre Marolleau, Brigitte Gubler, Vincent Goëb
BACKGROUND: The aim was to describe the regulatory B and T cells (Breg and Treg) and T helper 17 (Th17) lymphocytes before and under treatment with biologic drugs, and to assess their potential predictive value as biomarkers of response in rheumatoid arthritis (RA). METHODS: This was a non-randomised, single-centre, prospective study. Patients with active RA (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010) who required the initiation or switch to any biologic drug except rituximab were included...
February 10, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28178142/treatment-of-rheumatoid-arthritis-with-biologics-may-exacerbate-htlv-1-associated-conditions-a-case-report
#3
Yukiko Terada, Koju Kamoi, Kyoko Ohno-Matsui, Kazunori Miyata, Chinami Yamano, Ariella Coler-Reilly, Yoshihisa Yamano
RATIONALE: There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood. PATIENT CONCERNS AND DIAGNOSIS: An HTLV-1-infected 66-year-old female with HTLV-1 uveitis (HU) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Her HU had been in remission and her HAM/TSP symptoms had been managed effectively with oral steroids for years...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28150514/maintenance-treatment-using-abatacept-with-dose-reduction-after-achievement-of-low-disease-activity-in-patients-with-rheumatoid-arthritis-matador-a-prospective-multicenter-single-arm-pilot-clinical-trial
#4
Shinsuke Yasuda, Kazumasa Ohmura, Hiroshi Kanazawa, Takashi Kurita, Yujiro Kon, Tomonori Ishii, Yuichiro Fujieda, Satoshi Jodo, Kazuhide Tanimura, Michio Minami, Tomomasa Izumiyama, Takumi Matsumoto, Yoshiharu Amasaki, Yoko Suzuki, Hideki Kasahara, Naofumi Yamauchi, Masaru Kato, Tamotsu Kamishima, Akito Tsutsumi, Hiromitsu Takemori, Takao Koike, Tatsuya Atsumi
OBJECTIVES: To preliminarily evaluate the feasibility of maintenance therapy with reduced dose of intravenous abatacept (ABT) to 250mg/body/month after achieving remission or low disease activity (LDA). PATIENTS AND METHODS: RA patients treated with ABT at 13 sites were enrolled in this prospective interventional pilot study during the period between March 2013 and March 2015. Inclusion criteria were 1) age at 20 years or older, 2) under treatment with intravenous ABT monthly at approved doses, 3) DAS28-CRP lower than 2...
February 2, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28148840/therapy-with-ctla4-ig-and-an-antiviral-monoclonal-antibody-controls-chikungunya-virus-arthritis
#5
Jonathan J Miner, Lindsey E Cook, Jun P Hong, Amber M Smith, Justin M Richner, Raeann M Shimak, Alissa R Young, Kristen Monte, Subhajit Poddar, James E Crowe, Deborah J Lenschow, Michael S Diamond
In 2013, chikungunya virus (CHIKV) transmission was documented in the Western Hemisphere, and the virus has since spread throughout the Americas with more than 1.8 million people infected in more than 40 countries. CHIKV targets the joints, resulting in symmetric polyarthritis that clinically mimics rheumatoid arthritis and can endure for months to years. At present, no approved treatment is effective in preventing or controlling CHIKV infection or disease. We treated mice with eight different disease-modifying antirheumatic drugs and identified CLTA4-Ig (abatacept) and tofacitinib as candidate therapies based on their ability to decrease acute joint swelling...
February 1, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28141917/enhanced-bruton-s-tyrosine-kinase-activity-in-peripheral-blood-b-lymphocytes-of-autoimmune-disease-patients
#6
Odilia B J Corneth, Gwenny M P Verstappen, Sandra M J Paulissen, Marjolein J W de Bruijn, Jasper Rip, Melanie Lukkes, Jan Piet van Hamburg, Erik Lubberts, Hendrika Bootsma, Frans G M Kroese, And Rudi W Hendriks
OBJECTIVE: Bruton's tyrosine kinase (BTK) transmits crucial survival signals from the B cell receptor (BCR) in B cells. Pharmacological BTK inhibition effectively diminishes disease symptoms in mouse models of autoimmunity and, conversely, transgenic BTK overexpression induces systemic autoimmunity in mice. We investigated BTK expression and activity in human B cells in the context of autoimmune disease. METHODS: Using intracellular flow cytometry, we quantified BTK expression and phosphorylation in peripheral blood B cell subsets in patients with rheumatoid arthritis (RA; n=30) and primary Sjogren's Syndrome (pSS; n=26) and matched healthy controls...
January 31, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28109618/effects-of-dmards-on-citrullinated-peptide-autoantibody-levels-in-ra-patients-a-longitudinal-analysis
#7
Carolin Wunderlich, Isabelle Oliviera, Camille P Figueiredo, Juergen Rech, Georg Schett
OBJECTIVE: To study whether stable treatment with DMARDs affects anti-CCP2 antibody levels in patients with rheumatoid arthritis. METHODS: In this longitudinal observational study 100 RA patients were followed for anti-CCP2 IgG antibody (U/L) and total IgG level (mg/dL) every 6 months for a total period of 2.5 years. All patients received stable DMARD treatment during this period. Five groups comprising each 20 patients were analyzed as follows: (1) methotrexate (MTX) alone, (2) tumor necrosis factor inhibitors (TNFi), (3) tocilizumab (TCZ), (4) rituximab (RTX), and (5) abatacept (ABA)...
October 3, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28079510/a-comparison-of-discontinuation-rates-of-tofacitinib-and-biologic-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-a-systematic-review-and-bayesian-network-meta-analysis
#8
Sun-Kyeong Park, Min-Young Lee, Eun-Jin Jang, Hye-Lin Kim, Dong-Mun Ha, Eui-Kyung Lee
OBJECTIVES: The purpose of this study was to compare the discontinuation rates of tofacitinib and biologics (tumour necrosis factor inhibitors (TNFi), abatacept, rituximab, and tocilizumab) in rheumatoid arthritis (RA) patients considering inadequate responses (IRs) to previous treatment(s). METHODS: Randomised controlled trials of tofacitinib and biologics - reporting at least one total discontinuation, discontinuation due to lack of efficacy (LOE), and discontinuation due to adverse events (AEs) - were identified through systematic review...
January 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28058538/factors-influencing-the-choice-of-first-and-second-line-biologic-therapy-for-the-treatment-of-rheumatoid-arthritis-real-life-data-from-the-italian-lorhen-registry
#9
Sara Monti, Catherine Klersy, Roberto Gorla, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Raffaele Pellerito, Enrico Fusaro, Giuseppe Paolazzi, Pier Andrea Rocchetta, Ennio Giulio Favalli, Antonio Marchesoni, Roberto Caporali
According to international recommendations, the selection of the biologic disease modifying anti-rheumatic drug (bDMARD) for rheumatoid arthritis (RA) is mainly left to the clinician's preference. We analyzed the real-life factors influencing the first-line choice or the switching strategy, focusing on the prescription of abatacept (ABA) or tocilizumab (TCZ) compared to TNFα inhibitors (TNFi). Patients enrolled in the Lombardy Rheumatology Network (LORHEN) Registry after January 1, 2010, when all considered bDMARD agents were available, were included...
January 5, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28053274/safety-of-surgery-in-patients-with-rheumatoid-arthritis-treated-by-abatacept-data-from-the-french-orencia-in-rheumatoid-arthritis-registry
#10
Augustin Latourte, Jacques-Eric Gottenberg, Cécile Luxembourger, Isabelle Pane, Pascal Claudepierre, Pascal Richette, Pierre Lafforgue, Bernard Combe, Alain Cantagrel, Jean Sibilia, René-Marc Flipo, Philippe Gaudin, Olivier Vittecoq, Thierry Schaeverbeke, Maxime Dougados, Jeremie Sellam, Philippe Ravaud, Xavier Mariette, Raphaèle Seror
OBJECTIVE: To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA). METHODS: The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications...
January 3, 2017: Rheumatology
https://www.readbyqxmd.com/read/28043761/the-effect-of-body-mass-index-on-clinical-response-to-abatacept-as-a-first-line-biologic-for-rheumatoid-arthritis-6-month-results-from-the-2-year-observational-prospective-action-study
#11
Xavier Mariette, Rieke Alten, Hubert G Nüßlein, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars
OBJECTIVE: To assess the impact of baseline body mass index (BMI) on the efficacy and retention of intravenous abatacept at 6 months in biologic-naïve patients with rheumatoid arthritis (RA). METHODS: This was a 6-month analysis of a 2-year, non-interventional, international, prospective study. Baseline characteristics, clinical response and retention rates were compared by BMI subgroup: underweight/normal, overweight and obese (<25, 25 to <30 and ≥30kg/m(2), respectively)...
December 30, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28034349/biological-agents-in-rheumatoid-arthritis-a-cross-link-between-immune-tolerance-and-immune-surveillance
#12
Rossella Talotta, Fabiola Atzeni, Alberto Batticciotto, Maurizio Benucci, Sara Bongiovanni, Piercarlo Sarzi-Puttini
The biological drugs have all been successfully used to treat rheumatoid arthritis (RA) and have led to fair rates of clinical remission; however, the possible occurrence of adverse events such as infectious diseases or cancers means that the patients undergoing treatment need to be closely monitored. Anti-TNF agents, first appeared in the pharmacological algorithm of RA in the early 2000s, seem to lead to a higher risk of reactivated tubercular infection than the biological agents with different mechanism of action (abatacept or rituximab)...
December 30, 2016: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/28013201/risk-of-serious-adverse-effects-of-biological-and-targeted-drugs-in-patients-with-rheumatoid-arthritis-a-systematic-review-meta-analysis
#13
Simon Tarp, Daniel Eric Furst, Maarten Boers, George Luta, Henning Bliddal, Ulrik Tarp, Karsten Heller Asmussen, Birgitte Brock, Anna Dossing, Tanja Schjødt Jørgensen, Steffen Thirstrup, Robin Christensen
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28010149/outcomes-of-tumor-necrosis-factor-inhibitor-cycling-versus-switching-to-a-disease-modifying-anti-rheumatic-drug-with-a-new-mechanism-of-action-among-patients-with-rheumatoid-arthritis
#14
Benjamin Chastek, Laura K Becker, Chieh-I Chen, Puneet Mahajan, Jeffrey R Curtis
OBJECTIVES: To examine treatment patterns, treatment effectiveness, and treatment costs for 1 year after patients with rheumatoid arthritis switched from a tumor necrosis factor inhibitor (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), either cycling to another TNFi ("TNFi cyclers") or switching to a new mechanism of action (abatacept, tocilizumab, or tofacitinib) ("new MOA switchers"). METHODS: This retrospective cohort study used administrative claims data for a national insurer...
January 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/27974925/new-pharmacological-strategies-in-rheumatic-diseases
#15
REVIEW
Schiotis Re, Buzoianu Ad, Mureșanu Df, Suciu S
Targeting the pathogenic pathway of chronic inflammation represents an unmet challenge for controlling disease activity, preventing functional disability, and maintaining an adequate quality of life in patients with rheumatic diseases. Abatacept, a novel molecule that inhibits co-stimulation signal, induces an inhibitory effect on the T-cells. This will further interfere with the activity of several cell lines, leading to the normalization of the immune response. In the latest years, abatacept has been extensively investigated in studies of rheumatoid arthritis for which it was recently approved as a second line biologic treatment in Romania...
July 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27971460/a-cost-effectiveness-analysis-of-abatacept-tocilizumab-and-tnf-inhibitor-compared-with-rituximab-as-a-second-line-therapy-for-treatment-of-rheumatoid-arthritis
#16
S Huoponen, K J Aaltonen, J T Joensuu, J Rutanen, H Relas, K Taimen, K Puolakka, T Sokka, D Nordström, M Blom
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971459/economic-evaluation-of-tocilizumab-vs-abatacept-in-methotrexate-experienced-patients-with-rheumatoid-arthritis-in-italy
#17
S Villa, R Ravasio, F Rossetti, L Bianchino
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27966068/body-mass-does-not-impact-the-clinical-response-to-intravenous-abatacept-in-patients-with-rheumatoid-arthritis-analysis-from-the-pan-european-registry-collaboration-for-abatacept-panaba
#18
Florenzo Iannone, Delphine S Courvoisier, Jacques Eric Gottenberg, Maria Victoria Hernandez, Elisabeth Lie, Helena Canhão, Karel Pavelka, Merete Lund Hetland, Carl Turesson, Xavier Mariette, Denis Choquette, Axel Finckh
Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined the impact of body mass index (BMI) on the clinical effectiveness of abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis of 10 prospective cohorts of RA patients. All patients with available BMI were included in this study. The primary endpoint was drug retention of abatacept in the different BMI categories. Multivariable Cox regression was used to estimate hazard ratios (HRs) for drug discontinuation...
December 14, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27919316/corrigendum-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-not-previously-treated-with-disease-modifying-antirheumatic-drugs-and-after-the-failure-of-conventional-disease-modifying
#19
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo
No abstract text is available yet for this article.
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27914689/efficacy-of-biologic-therapy-across-individual-juvenile-idiopathic-arthritis-subtypes-a-systematic-review
#20
REVIEW
Rebecca Davies, Danielle Gaynor, Kimme L Hyrich, Clare E Pain
OBJECTIVE: To determine the efficacy of differing biologic therapies amongst individual juvenile idiopathic arthritis (JIA) subtypes rather than JIA overall. METHODS: A systematic literature review was conducted between January 1975 and November 2014. Studies included were randomised controlled trials, controlled trials, non-randomised prospective studies or case-control studies. Subjects were required to have a diagnosis of JIA and were ≤20 years of age at study entry...
November 1, 2016: Seminars in Arthritis and Rheumatism
keyword
keyword
94163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"